Replies to post #44320 on Biotech Values

[quantumdot]

>"Unfortunately, DNDN data did not demonstrate actual survival. I carefully reviewed DNDN data. The data is very weak....<

Gee, you really sound like you know what you're talking about. I think I'll take you seriously.


>"Advisory Committee voted 13-4 to recommend DNDN's Provenge immunotherapy for prostate cancer with very limited data (only 82 treated patients with just 21% increase in survival). This is good. The last weekend I attended a casino and played a roulette. At one moment "RED" numbers came 11 times out of 12 spins. This did and could happened only because the sampling was very small. However, my experience does not in any way invalidate laws of mathematics. "<

Upon searching I found this other analytic jewel of yours. Your grasp of biostatistics is awe inspiring.

[AlpineBV_Miller]

"I carefully reviewed DNDN data. The data is very weak. "

Congrats on being smarter than the FDA reviewers and 13 of 17 experts assembled by the FDA who reviewed the data.